The common target PPI network analysis showed that the key targets of the SZHP in the treatment of dyslipidemia included CCND1, CASP3, HIF1A, ESR1, ERBB2, MYC, PTEN, TP53, AKT1, and EGFR. This evidence concerns the gene ERBB2 and metabolic syndrome.